Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 125

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 125
---
 are able to raise sufficient capital and potentially
license or acquire new technologies, product development costs may also increase if we experience delays in testing or marketing approvals.
We do not know whether preclinical studies or clinical trials will need to be restructured or will be completed on schedule, or at all.
Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
product candidates or may allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
new product candidates and may harm our business and results of operations. In addition, enrollment delays in clinical trials may result
in increased development costs, which would cause the value of the Company to decline and limit our ability to obtain additional financing.

If serious adverse events or unacceptable side
effects are identified during the development of any product candidates, we may need to abandon or limit our development of those future
product candidates. 

If any potential product candidates are associated
with undesirable effects in preclinical or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay
or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Currently unknown, drug-related side
effects may be identified in our planned clinical studies and, as such, these possible drug-related side effects could affect patient
recruitment, the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Reported serious
adverse events may arise and the occurrence, whatever the cause, may impact the conduct of any ongoing or future clinical trial. To date,
we have had no product candidates evaluated in any human clinical studies. Any occurrence of clinically significant adverse events may
harm our business, financial condition and prospects significantly.

Our business and operations would suffer in the
event of computer system failures, cyber-attacks or deficiencies in our or third parties’ cyber security.

Given our limited operating history and limited capital,
we are still in the process of implementing our internal security measures. Our internal computer systems and those of current and future
third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology
and other planned internal infrastructure systems, including corporate firewalls, servers, connection to the Internet, face the risk of
systemic failure that could disrupt our operations. If such an event were to occur and cause interruptions in